Novartis   link
Location: Basel
Hauptporte - MainGate, Fabrikstrasse 2, 4056 Basel

Discipline: Pharmacology

Research & Development at Novartis The Novartis Pharmaceuticals clinical pipeline holds a broad stream of 140 future projects including both new molecular entities and additional indications or formulations for marketed products. Our pipeline has consistently being ranked by experts as one of the strongest in the industry. Our scientists focus on diseases for which medical need remains unmet and strive to improve the drug discovery process with an approach that integrates novel concepts and tools across multiple disease areas.


Pharmacology - Health - Sep 19
Based on unprecedented progression-free survival results, Tafinlar (dabrafenib) + Mekinist (trametinib) confirmed as standard-of-care, targeted therapy for advanced BRAF-mutated melanoma 1-4 -   Data show positive durable responses and progression-free survival benefit for patients treated with Tafinlar + Mekinist in the comparator arm of the CO
Pharmacology - Health - Sep 19

In SOLAR-1 final analysis, Piqray (alpelisib) plus fulvestrant demonstrated 8 months clinically relevant improvement in overall survival (OS) in HR+/HER2- advanced breast cancer (aBC) patients with a PIK3CA mutation compared to fulvestrant alone 1 -   14+ months OS improvement was achieved in patients with lung or liver metastases, which are obs

Pharmacology - Health - Sep 16

COMBI-AD is first trial to demonstrate 5-year relapse-free survival with targeted therapy as adjuvant treatment in high-risk patients with stage III BRAF-mutated melanoma 1 -   Adjuvant treatment with standard-of-care targeted therapy Tafinlar + Mekinist reduced the risk of relapse or death by 49% compared to placebo 1 -   Updated data show Tafi

Pharmacology - Health - Sep 14

In Phase III KITE study, Beovu (brolucizumab) 6 mg achieved its primary endpoint of non-inferiority to aflibercept 2 mg in mean change in best-corrected visual acuity (BCVA) at year one (week 52)1 -   In a key secondary endpoint, more than half of Beovu patients were maintained on a three-month dosing interval through year one, following the loa

Pharmacology - Health - Sep 11

Post hoc EXPAND analysis showed improvements in cognitive processing speed in patients with active and non-active SPMS treated with Mayzent 1 -   Subgroup analyses of the EXPAND trial showed the value of early treatment initiation with Mayzent in patients with active SPMS as positive effects on disability, cognitive processing speed and relapse

Pharmacology - Health - Sep 7

High-dose, once-daily Enerzair Breezhaler [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks 1 Once-daily Enerzair Breezhaler, which includes an optional digital companion (sensor and app), is the first LABA/LAMA/ICS* fixed-dose combination approved for patients whose ast

Health - Economics - Sep 16

First healthcare industry sustainability-linked bond (SLB) further embeds Environmental Social Governance (ESG) targets into the core of Novartis business operations SLB linked to 2025 Patient Access Targets to increase patients reached in lowand middle-income countries (LMICs) with strategic innovative therapies by 200% and the Novartis Flagshi

Pharmacology - Health - Sep 14

Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD   -   The update includes the additional characterization of retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation 1 -   Novartis has established a multidisciplinary panel o

Pharmacology - Health - Sep 11

New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide 1 Additional safety data in over 1,800 patients who continued Kesimpta treatment or s

Pharmacology - Health - Sep 8

Novartis will present 48 abstracts from its leading MS portfolio, including new data on recently FDA-approved Kesimpta (ofatumumab) -the first and only self-administered, targeted B-cell therapy for relapsing forms of MS (RMS )- Mayzent (siponimod) and Gilenya (fingolimod) -   New pivotal data from ASCLEPIOS trials evaluating the efficacy and sa

Pharmacology - Health - Sep 2

Tabrecta(TM) (capmatinib, formerly INC280) is the first and only therapy approved by the FDA to specifically target metastatic non-small cell lung cancer (NSCLC) with a mutation that leads to MET exon 14 skipping (METex14) METex14 is an important biomarker for physicians to consider when selecting metastatic NSCLC treatment options 1 -   In the